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Abstract
Background: There is a high incidence of diarrhea in traveling populations. Norovirus (NV) infection is a common 
cause of diarrhea and is associated with 7% of all diarrhea related deaths in the US. However, data on the overall 
prevalence of NV infection in traveling populations is limited. Furthermore, the prevalence of NV amongst travelers 
returning to Europe has not been reported. This study determined the prevalence of NV among international travelers 
returning to Germany from over 50 destinations in and outside Europe.
Methods: Stool samples of a total of 104 patients with a recent (< 14days) history of international travel (55 male, mean 
age 37 yrs.) were tested for the presence of NV genogroup (GG) I and II infection using a sensitive and well established 
quantitative RT PCR method. 57 patients experienced diarrhea at the time of presentation at the Department of 
Infectious Diseases & Tropical Medicine. The remaining 47 patients had no experience of diarrhea or other 
gastrointestinal symptoms for at least 14 days prior to their date of presentation at our institute.
Results: In our cohort, NV infection was detected in 15.7% of returning travelers with diarrhea. The closer to the date of 
return symptoms appeared, the higher the incidence of NV, ranging as high as 21.2% within the first four days after 
return.
Conclusions: In our cohort, NV infection was shown to be frequent among returning travelers especially in those with 
diarrhea, with over 1/5 of diarrhea patients tested positive for NV within the first four days after their return to Germany. 
Due to this prevalence, routine testing for NV infection and hygienic precautions may be warranted in this group. This is 
especially applicable to patients at an increased risk of spreading the disease, such as healthcare workers, teachers or 
food-handlers.
Background
An increased incidence of diarrhea can be detected in
traveling populations [1]. In industrialized countries
noroviruses (NV) are presently recognized as the most
common cause of diarrhea in the adult population, both
for epidemic [2] and sporadic [3] cases of diarrhea. It is
estimated that they cause up to 85% of all viral enteritis
worldwide [4]. Despite the high rate of recovery generally
associated with NV infection, up to 7% of all diarrhea-
related deaths in the US are thought to be caused by NV
[5]. Thus, NV enteritis can be expected to cause signifi-
cant human and economic loss [6,7] which could be exac-
erbated in patients suffering co-morbid conditions.
Judging by two studies carried out in 2002 and in 2008
the economic and human impact that NV spread by trav-
elers has on European public health systems appears to be
substantial[8,9]. As with any rapidly mutating viral agent
where pandemics due to newly emerging genotypes are
reported nearly every two years, travelers are expected to
significantly contribute to the spread of NV. A number of
infected pilgrims returning from Lourdes was shown to
cause more than 380 secondary cases including one fatal-
ity in 29 Swiss nursery homes [8]. In addition, 130 sec-
ondary cases, nine outbreaks and four deaths across
France, the Netherlands and Ireland were directly attrib-
utable to epidemic enteritis spread by returning pilgrims
from Lourdes [9].
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RT-PCR methods have been recognized as the gold
standard of NV detection [10-12]. A report of 35 patients
with diarrhea that traveled from the US to Mexico in
2005 showed the exceptionally high rate of NV infection
of 65% using a sensitive RT-PCR method [13]. In con-
trast, previous studies reported infection rates of only 5-
15% in travelers suffering diarrhea in the 1980's using
radioimmunoassay methods [14-16]. In spite of the dis-
crepancies in the prevalence of NV infection reported
amongst travelers, the data suggests that travelers are a
particular group that is susceptible to NV infection. This
warrants further investigation, especially since, to the
best of our knowledge, no data has been published assess-
ing the prevalence of NV amongst European traveling
populations. By providing data on the scale of the prob-
lem at hand, the study of prevalence rates of NV infection
among international travelers returning to Europe will
significantly contribute to assessing the impact NV
infected travelers have on European public health sys-
tems.
Methods
Fresh stool samples from 104 recently (< 14days)
returned travelers with and without diarrhea were col-
lected from August 2006 through May 2008 at the
Department of Infectious Diseases and Tropical Medi-
cine in Munich, Germany.
Sample preservation was performed as previously
reported for NV preservation from stool [17-21], creating
a 20% suspension of the sample in nuclease-free water
and storing samples at -80°C until testing. RNA extrac-
tion was carried out on the same day of RT-PCR testing.
In short, the stool suspension was diluted to 10% using
nuclease-free water and centrifuged at 3500 g for 10 min-
utes. RNA extraction was carried out using the „Micro-
labStar“ robot by Hamilton (Bonaduz, Switzerland) and
the QiAmp biorobot kit by Qiagen (Hilden, Germany),
following the manufacturers manual.
Samples were tested for NV genogroups I and II follow-
ing a standard qRT-PCR protocol at the 'State Depart-
ment for Health and Food Safety' as previously published
[18]. Qiagen One Step RT-PCR kit was used, following
the manufacturers protocols. Primers were synthesized
by MWG Biotech (Ebersberg, Germany). Primers NV
192, NV 193 and probe TM8 were used for the detection
of genogroup (GG) I viruses and primers 107a, NV 117
(corresponding to NV 119 in [18]) and probe TM3 for the
detection of GGII (tab. 1). Reference dye of the reaction
was "ROX" (Invitrogen, Karlsruhe, Germany).
Ethical clearance for the study was sought through the
Ethical Committee of the Medical Faculty at Ludwig-
Maximilians University, Munich, Germany. Clinical and
laboratory data was used only in the case that patients
had provided written informed consent to participate in
this study or after written informed consent was obtained
from the legal caretakers in the case of minors.
Statistical evaluation was carried out using SPSS 13.0
for Windows "student version" as well as standard appli-
cations of Microsoft Excel Version 2003.
Results
Of the 104 patients included in this study 55 were male.
Sex was evenly distributed between patients with and
without diarrhea (p = 0.652; chi-square test). The study
included patients from 4 to 80 years of age (mean 37.8 ±
14.7 yrs) without significant differences between patients
with and without diarrhea (p = 0.473; one-way Anova
test). The mean duration of the journey was comparable
in patients with and without diarrhea (p = 0.949 one-way
Anova test) with 69 and 71 days, respectively. (tab. 2)
Overall 10 cases of NV infection were detected in this
study, nine of which were found in patients with diarrhea
(15.7%), and one in the group of patients without diarrhea
(2.1%). Of the 10 cases of NV detected, eight were caused
by GGII viruses alone, one was a coinfection with GGI
and GGII and one case was an infection caused by GGI
alone. As expected, the difference in the number of NV
infections proved significant when comparing patients
with and without diarrhea (p = 0.019 by chi-square test).
Both sexes were equally likely to be infected (p = 0.210,
chi-square test). (tab. 2)
Of the nine positively tested patients that suffered diar-
rhea the following symptoms in addition to diarrhea were
reported to the observing physician: fever (2), abdominal
cramping (2), nausea (4), vomiting (2), headache (2) and
myalgia (2).
Patients in this study visited a total of over 50 destina-
tions. Traveling modality was shown to influence the
o d d s  o f  i n f e c t i o n .  A l l  p a t i e n t s  w i t h  d i a r r h e a  a n d  2 0
patients without diarrhea provided information as to
their traveling modalities. Overall, 28 patients (36%) had
taken part in a back-packing/adventure trip, 19 (25%) had
participated in a packaged holiday, 13 (17%) had been on
a business trip and eight (10%) were visiting friends and
family. All other patients that gave information as to their
way of traveling had either traveled as missionaries or
exchange students. Comparing traveling modalities
within the group of recently returned travelers with diar-
rhea, the backpacking trip was associated with the high-
est risk of a positive NV test result, when compared to
other forms of traveling (OR = 4.923). The business trip
carried the second highest risk of infection (OR = 1.429),
and those who had traveled on a packaged holiday carried
the lowest risk of a positive test result (OR = 0.304). (tab.
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It took patients with diarrhea 4.7 ± 3.0 days (minimum
0, maximum 13; 95% confidence interval 3.92-5.52 days)
and patients without diarrhea 5.3 ± 3.5 days (min. 0, max.
14; 95% confidence interval 4.32-6.36 days) to present at
our clinic for the first time after returning to Germany.
These time spans are comparable for both groups (p =
0.330 One-way Anova test). (tab. 2) Eight of the nine pos-
itively tested patients with diarrhea had visited the clinic
within the first five days after their return. Five of nine
diarrhea patients which were tested positive claimed to
have suffered from diarrhea since before their return to
Germany, the remaining four declared to have started
experiencing symptoms within the first four days after
their return. (Fig. 1) 21.2% of diarrhea patients tested for
NV within the first four days after their return to Ger-
many tested positive. There was no significant correlation
between the duration of the journey and the likelihood of
NV infection.
Discussion
NV enteritis is generally recognized as an acute self-limit-
ing disease inducing vomiting and watery non-bloody
diarrhea lasting 12 to 60 hours. Recovery is usually com-
plete and complications are rare in the non-comorbid
adult population [12,22-25]. However, it has been shown
that infants, elderly and immunocompromised patients,
and those suffering cardiovascular disease are signifi-
cantly more likely to experience a complicated or fatal
Table 1: Primer sequences. Primer sequences used for the detection of norovirus. Primers for both genotypes target the 
ORF1/ORF2 overlap of the viral genome.
Genogroup Primer Sequence Location*
G I NV 192 5'- gC (CT) Atg TTC CgC Tgg Atg C - 3' 5282 - 5300
G I NV 193 5'- CgT CCT Tag ACg CCA TCA TCA - 3' 5379 - 5359
G I TM8 5'- FAM - Tgg ACA gg(Ag) gAT CgC (Ag)AT 5321 - 5345
Probe CTC CTg C - 3' - TMR
G II NV 107a 5'- AgC CAA TgT TCA gAT ggA Tg - 3' 5007 - 5026
G II NV 117 5'- TCg Acg CCA TCT TCA TTC AC-3' 5100 - 5081
G II TM3 5'- FAM - Tgg gAg ggC gAT CgC AAT CTg gC - 5048 - 5070
Probe 3' - TMR
*Genome location of primers and probes are based for GI on the sequence of Norwalk/68/US [GenBank: M87661] and for GII on the sequence 
of Lordsdale/93/UK [GenBank: X86557];
Table 2: Overview of results. Demographic data and frequency of norovirus (NV) infection in recently returned travelers 
with diarrhea and in a control group of recently returned travelers without diarrhea:
Patients with diarrhea
(n = 57)
Asymptomatic patients
(n = 47)
Differences 
between groups
Male 29 26 p = 0.652
Mean age (yrs) 38.7 ± 15.7 36.6 ± 13.4 p = 0.437
Mean duration of journey (days) 68.5 ± 166 71.2 ± 266 p = 0.949
NV infection 9 (15.7%) 1 (2.1%) p = 0.019
GGI 10
GGII 71
GGI + GGII coinfection 10
Traveling modality and corresponding 
odds of infection
Backpacking trip: OR = 4.923
Business trip: OR = 1.429
Packaged holiday: OR = 0.304
Time until presentation at clinic after 
return (in days)
4.7 ± 3.0 5.3 ± 3.5 p = 0.330
India (total/NV+) 13/4 8/1
Backpacker (total/NV+) 22/6 6/0Apelt et al. BMC Infectious Diseases 2010, 10:131
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course [12,26]. The most common consequence of the
disease is dehydration, even though secondary complica-
tions as diverse as aspiration pneumonia, renal failure,
mucositis and acute abdomen have been described
[12,26].
Pandemics caused by newly emerged genotypes of NV,
in particular genotype GII.4, have been reported approxi-
mately every two years since 2002 [27]. This is thought to
be due to the high mutation potential of NV. Indeed the
mutation rate of NV has been quoted to be significantly
higher than that of influenza viruses [28]. The present
study shows a high rate of NV infection in travelers
returning to Germany suffering diarrhea. Overall, 15.7%
of diarrhea patients were infected with the virus. As a
comparison, only four in 79 travelers (2%) returning from
the US to Sweden with respiratory symptoms were shown
to suffer from influenza type A (H1N1) in a recent survey
[29].
Our results support previous findings of a high preva-
lence of NV among US travelers for the first time in a
European population and compare to findings quoted in
a recent review [30]. Furthermore we show that in this
population, the closer to the date of return diarrhea
developed, the higher the rate of NV+ cases, reaching
21% for patients suffering diarrhea within four days after
their return.
NV is a common cause of diarrhea in the adult popula-
tion. Thus, when evaluating the frequency of NV in a
traveling population it should always be kept in mind that
NV may be equally prevalent in a non-traveling popula-
tion. In an unpublished in-house study at the Department
of Infectious Diseases and Tropical Medicine the preva-
lence of NV unrelated to travel was assessed in 48 diar-
rhea patients using the method described in this paper
(personal communication). As the largest part of patients
at our clinic possesses a clinical history of recent travel, a
cut-off point was established to define patients whose
symptomatic NV infection was unlikely to be linked to
travel. This cut-off point was chosen at 14 days after
return from the last international journey and NV infec-
tions in patients that presented to the clinic 14 days or
more after their return were considered to be unrelated
to travel. This choice was based on the maximum incuba-
tion time reported for NV that was estimated at 130
hours [31] and the mean duration of symptoms for the
common GII.4 virus group that was reported to average
69 hours [32]. In this group of 48 diarrhea patients a sin-
gle patient has been found to suffer NV infection (2.1%).
The low prevalence in this cohort may indicate that trav-
eling might be an independent risk factor for the contrac-
tion of NV.
It was a special interest of ours to identify those diar-
rhea patients at highest risk for NV among the inhomo-
geneous group of returning travelers. The Department of
Infectious Diseases and Tropical Medicine routinely col-
lects data on the mode of traveling of patients. Hence, we
could observe participants in backpacking/adventure
trips to be the most likely to have contracted NV infec-
tion when compared to other returning travelers with
diarrhea (OR = 4.923). Having traveled on a packaged
holiday lowered the likelihood of NV when experiencing
diarrhea (OR = 0.304). We also consider it remarkable for
30.1% of returnees from India suffering diarrhea to have
been tested NV+, even though we are fully aware of the
fact that the scale of this investigation does not allow any
conclusions as to the likelihood with which NV affects
visitors to specific destinations.
Conclusion
A prevalence of NV of 21.2% among diarrhea patients
within the first four days after their return from an inter-
national journey may be sufficiently high to warrant rou-
tine testing for NV in this group. Recent studies suggest
that NV is continuously shed for an average of 28 days
after symptoms subside [31], even though detection tech-
niques may oftentimes not be sensitive enough to detect
viral shedding for more than 14 days after the end of
symptoms. However, bearing in mind that 10-100 viral
particles are sufficient to induce symptomatic NV infec-
tion [33,34] it is highly likely that patients remain infec-
tious for all of the 28 days that virus may be shed. Thus
routine NV testing in populations where NV is highly
prevalent may serve as a measure of public health preven-
tion. It allows doctors to take preventive action in the
case of a positive test result, especially were persons at
increased risk for spreading the disease such as health
care workers, teachers and food handlers are concerned.
Figure 1 Symptom duration in relation to the date of return. 
Graphic representation of the start date of gastrointestinal symptoms 
for all nine returning travelers with diarrhea. Patients enlisted as Pa-
tients 1 and 2 in this graph have claimed to have suffered from gastro-
intestinal symptoms for more than ten days before their return to 
Germany.
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